ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Eyetech Pharmaceuticals (MM)

Eyetech Pharmaceuticals (MM) (EYET)

0,00
0,00
(0,00%)
Fermé 22 Novembre 10:00PM
0,00
0,00
( 0,00% )
Avant marché: -

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

Dernier
-
Prix Achat
-
Prix Vente
-
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Clôture Veille
-
Ouverture
-
Dernière Transaction
Dernière heure de transaction
-
Volume moyen (3 m)
-
Volume financier
-
VWAP
-

EYET Dernières nouvelles

OSI Pharmaceuticals and Eyetech Pharmaceuticals Confirm November 14th Closing

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Eyetech Pharmaceuticals, Inc. (NASDAQ: EYET) today announced that the closing of the OSI acquisition of Eyetech will occur on Monday, November...

Eyetech Provides Update on Status of Pending Acquisition by OSI Pharmaceuticals

Stockholders Overwhelmingly Approve Merger NEW YORK, Nov. 10 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET) provided an update today on the status of its pending...

Eyetech Reports Third Quarter 2005 Financial Results

Company achieves operating profitability, excluding certain charges, based on total revenue of $67.4 million and net product revenue of $55.5 million NEW YORK, Oct. 31 /PRNewswire-FirstCall/...

Eyetech Announces Enrollment of the First Patient in a Phase 3 Clinical Trial of Macugen(R) (pegaptanib sodium injection) in Dia

Phase 2 study of Macugen in diabetic macular edema (DME) published in the October issue of Ophthalmology NEW YORK, Oct. 17 /PRNewswire-FirstCall/ .- Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET...

Recent Analyses Suggest That Treatment With Macugen(R) (pegaptanib sodium injection) May Provide Better Results for Patients Wit

Retrospective, subgroup analyses of the VISION study suggest that treatment of early disease with Macugen may further reduce the risk of vision loss associated with neovascular AMD compared to the...

Macugen(R) (pegaptanib sodium injection) Receives Positive Opinion for Treatment of Neovascular Age-Related Macular Degeneration

NEW YORK, Sept. 16 /PRNewswire-FirstCall/ -- Eyetech Pharmaceuticals, Inc. (NASDAQ:EYET) announced today that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee...

OSI Pharmaceuticals and Eyetech Pharmaceuticals Announce Signing of Definitive Merger Agreement

Acquisition Projected to be Accretive and Generate Combined 2006 Revenues of Over $600 Million MELVILLE, N.Y. and NEW YORK, Aug. 21 /PRNewswire-FirstCall/ -- OSI Pharmaceuticals, Inc...

OSI Pharmaceuticals and Eyetech Pharmaceuticals Announce Signing of Definitive Merger Agreement; Acquisition Projected to be Acc

OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Eyetech Pharmaceuticals, Inc. (NASDAQ: EYET) today announced that they have entered into a definitive merger agreement whereby OSI has agreed...

Macugen(R) (pegaptanib sodium injection) Named Innovative Pharmaceutical Product Of The Year At The 2005 Pharmaceutical Achievem

Award recognizes Macugen's breakthrough technology as the first anti- angiogenic treatment approved in ophthalmology and the first aptamer therapy approved by the FDA NEW YORK, Aug. 9...

Eyetech Reports Second Quarter 2005 Financial Results

Eyetech Reports Second Quarter 2005 Financial Results - Gross Product Revenue for Macugen(R) (pegaptanib sodium injection) increased to $50 million in the second quarter from $25 million in the...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
WCTWellchange Holdings Company Limited
US$ 2,37
(89,60%)
12,56M
VRPXVirpax Pharmaceuticals Inc
US$ 0,9533
(61,66%)
11,85M
SJWSJW Group
US$ 87,99
(58,97%)
40
NSTSNSTS Bancorp Inc
US$ 17,72
(58,36%)
8
IMOSChipMOS Technologies Inc
US$ 27,99
(44,28%)
4
KELYAKelly Services Inc
US$ 7,11
(-48,92%)
1
ENTAEnanta Pharmaceuticals Inc
US$ 5,01
(-46,19%)
117
FNWBFirst Northwest Bancorp
US$ 6,01
(-45,71%)
1
WAFDWaFd Inc
US$ 21,82
(-39,97%)
28
KSCPKnightscope Inc
US$ 11,08
(-39,42%)
13,69k
WCTWellchange Holdings Company Limited
US$ 2,37
(89,60%)
12,56M
VRPXVirpax Pharmaceuticals Inc
US$ 0,9533
(61,66%)
11,85M
BENFBeneficient
US$ 1,10
(25,00%)
8,1M
RGTIRigetti Computing Inc
US$ 1,78
(20,27%)
7,06M
SKKSKK Holdings Limited
US$ 1,42
(29,09%)
4,44M
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock